Citation Impact
Citing Papers
Diversity and Complexity in DNA Recognition by Transcription Factors
2009 Science
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
2009
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Emerging therapies for the treatment of hepatitis C
2013 StandoutNobel
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
2015
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
2013
Mucroporin-M1 Inhibits Hepatitis B Virus Replication by Activating the Mitogen-activated Protein Kinase (MAPK) Pathway and Down-regulating HNF4α in Vitro and in Vivo
2012
Effect of Surface Properties on Nanoparticle–Cell Interactions
2009 Standout
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Cell Penetrating Peptides: Intracellular Pathways and Pharmaceutical Perspectives
2007
CpG islands and the regulation of transcription
2011 Standout
Protein nanoparticles as drug carriers in clinical medicine
2008
The biology and management of non-small cell lung cancer
2018 StandoutNature
Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides
2004
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Twenty years of cell‐penetrating peptides: from molecular mechanisms to therapeutics
2009
A review of stimuli-responsive nanocarriers for drug and gene delivery
2008 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
Hepatitis C Virus RNA Replication
2013
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
2017
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
2017 Standout
The Human Transcription Factors
2018 Standout
Predicting the sequence specificities of DNA- and RNA-binding proteins by deep learning
2015 Standout
Mapping and analysis of chromatin state dynamics in nine human cell types
2011 StandoutNature
Macrophages in atherosclerosis: a dynamic balance
2013 Standout
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments
2017
The design of guanidinium-rich transporters and their internalization mechanisms
2007
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Cell penetration properties of maurocalcine, a natural venom peptide active on the intracellular ryanodine receptor
2006
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
2017
Controlled drug delivery vehicles for cancer treatment and their performance
2018 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
2016
Non-viral vectors for gene-based therapy
2014 Standout
Annotation of functional variation in personal genomes using RegulomeDB
2012 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Conservation and regulatory associations of a wide affinity range of mouse transcription factor binding sites
2010
A Cell-Penetrating Scorpion Toxin Enables Mode-Specific Modulation of TRPA1 and Pain
2019 StandoutNobel
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
Receptor-Mediated Gene Transfer Vectors: Progress Towards Genetic Pharmaceuticals
2003
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Evaluation of transportan 10 in PEI mediated plasmid delivery assay
2005
Thermo- and pH-responsive polymers in drug delivery☆
2006 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Transactivating transcriptional activator-mediated drug delivery
2006
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
2005 Standout
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
2013
Application of Novel Solid Lipid Nanoparticle (SLN)-Gene Vector Formulations Based on a Dimeric HIV-1 TAT-Peptide in Vitro and in Vivo
2004
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
2015
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA
2015 StandoutNobel
Cancer-related inflammation and treatment effectiveness
2014 Standout
Delivery of bioactive molecules into the cell: the Trojan horse approach
2004
Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
2014
In vitro and in vivo gene transfer with poly(amino acid) vesicles
2003
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Endocytosis of nanomedicines
2010 Standout
Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology
2013
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture
2016 StandoutNobel
MicroRNA-33–dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis
2015
The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity
2022 StandoutNobel
RECENT APPROACHES TO INTRACELLULAR DELIVERY OF DRUGS AND DNA AND ORGANELLE TARGETING
2006
Intracellular Protein Delivery System with Protein Needle–GFP Construct
2014 StandoutNobel
Macrophage Polarization
2016 Standout
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Nonviral Vectors for Gene Delivery
2008 Standout
Antiangiogenesis beyond VEGF inhibition: A journey from antiangiogenic single-target to broad-spectrum agents
2013
Recent Developments in Peptide-Based Nucleic Acid Delivery
2008
The Versatile Role of microRNA-30a in Human Cancer
2017 Standout
Treating Patients With EGFR-Sensitizing Mutations: First Line or Second Line—Is There a Difference?
2013
Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers
2021 StandoutNobel
Cellular Internalization and Distribution of Arginine-Rich Peptides as a Function of Extracellular Peptide Concentration, Serum, and Plasma Membrane Associated Proteoglycans
2008
Polymer–drug conjugation, recent achievements and general strategies
2007
Oligonucleotide-Modified Gold Nanoparticles for Intracellular Gene Regulation
2006 StandoutScience
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
2016
Single-Molecule Motions of Oligoarginine Transporter Conjugates on the Plasma Membrane of Chinese Hamster Ovary Cells
2008 StandoutNobel
Macrophage plasticity, polarization, and function in health and disease
2018 Standout
Peptide-Enhanced Nucleic Acid Delivery
2005
Works of Sergey Orlov being referenced
Novel repressor of the humanFMR1gene − identification of p56 human (GCC)n‐binding protein as a Krüppel‐like transcription factor ZF5
2007
Receptor-Mediated Transfer of DNA–Galactosylated Poly-L-lysine Complexes into Mammalian Cells in vitro and in vivo
2001
Complexes of Plasmid DNA with Basic Domain 47-57 of the HIV-1 Tat Protein Are Transferred to Mammalian Cells by Endocytosis-mediated Pathways
2003
Peroxisome Proliferator-activated Receptor α Positively Regulates Complement C3 Expression but Inhibits Tumor Necrosis Factor α-mediated Activation of C3 Gene in Mammalian Hepatic-derived Cells
2012
O-101 XYOTAX™/carboplatin vs paclitaxel/carboplatin for the treatmentof PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The stellar 3 phase III study
2005
Smoking status to predict sensitivity to PARP inhibitor, veliparib, in patients with advanced NSCLC.
2015
Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: Results from the phase III SELECT-1 trial
2016
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
2012
A Randomized, Double-Blind, Phase 2 Trial of Veliparib (Abt-888) with Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer
2014
ASCEND-3: A single-arm, open-label, multicenter phase II study of ceritinib in ALKi-naïve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC).
2015
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
2012
Endogenous apolipoprotein A‐I stabilizes ATP‐binding cassette transporter A1 and modulates Toll‐like receptor 4 signaling in human macrophages
2012
A Randomized, Double-Blind, Phase 2 Trial of Veliparib (ABT-888) With Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer
2014
Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)
2007
Role of the Nuclear Receptors HNF4α, PPARα, and LXRs in the TNFα-Mediated Inhibition of Human Apolipoprotein A-I Gene Expression in HepG2 Cells
2009
Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial.
2013
Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
2016